about
Giant osteoclast formation and long-term oral bisphosphonate therapySynthesis of Hydroxymethylenebisphosphonic Acid Derivatives in Different SolventsTargeted Delivery Systems for Molecular Therapy in Skeletal DisordersPrevention and treatment of bone fragility in cancer patientBisphosphonate Related Osteonecrosis of the Jaw: An UpdateA novel EST-derived RNAi screen reveals a critical role for farnesyl diphosphate synthase in β2-adrenergic receptor internalization and down-regulationSynergistic action of statins and nitrogen-containing bisphosphonates in the development of rhabdomyolysis in L6 rat skeletal myoblastsRole of Rab GTPases in membrane traffic and cell physiologyMulticystic bone disease (Gorham-Stout syndrome) in a spider monkey (Ateles geoffroyi ).Selectivity in bone targeting with multivalent dendritic polyanion dye conjugates.Targeting angiogenesis-dependent calcified neoplasms using combined polymer therapeuticsThe role of muscle loading on bone (Re)modeling at the developing enthesis.Osteoclast profile of medication-related osteonecrosis of the jaw secondary to bisphosphonate therapy: a comparison with osteoradionecrosis and osteomyelitis.Giant osteoclasts after long-term bisphosphonate therapy: diagnostic challengesReduced osteoclastogenesis and RANKL expression in marrow from women taking alendronate.Inherited multicentric osteolysis: case report of three siblings treated with bisphosphonateAnti-Tumor Activity and Immunotherapeutic Potential of a Bisphosphonate Prodrug.Unusual Idiopathic Calcinosis Cutis Universalis in a Child.Current and emerging treatments for the management of osteogenesis imperfecta.Ewing sarcoma cells express RANKL and support osteoclastogenesis.The two faces of serotonin in bone biology.Clusterin inhibition using OGX-011 synergistically enhances zoledronic acid activity in osteosarcomaRisk of fracture and the concomitant use of bisphosphonates with osteoporosis-inducing medications.Long-term efficacy, safety, and patient acceptability of ibandronate in the treatment of postmenopausal osteoporosisBreast cancer at bone metastatic sites: recent discoveries and treatment targets.Farnesyl diphosphate synthase is involved in the resistance to zoledronic acid of osteosarcoma cellsZoledronic acid in breast cancer: latest findings and interpretationsTiludronate treatment improves structural changes and symptoms of osteoarthritis in the canine anterior cruciate ligament modelIncidence and risk predictors for osteonecrosis of the jaw in cancer patients treated with intravenous bisphosphonatesRisk of atrial fibrillation among bisphosphonate users: a multicenter, population-based, Italian study.Pluronics-Formulated Farnesol Promotes Efficient Killing and Demonstrates Novel Interactions with Streptococcus mutans Biofilms.Non-Ototoxic Local Delivery of Bisphosphonate to the Mammalian Cochlea.National Cancer Institute, National Heart, Lung and Blood Institute/Pediatric Blood and Marrow Transplantation Consortium First International Consensus Conference on late effects after pediatric hematopoietic cell transplantation: the need for pediaBasal and therapy-driven hypoxia-inducible factor-1α confers resistance to endocrine therapy in estrogen receptor-positive breast cancer.The effects of zoledronate on the survival and function of human osteoblast-like cellsParathyroid hormone regulates the distribution and osteoclastogenic potential of hematopoietic progenitors in the bone marrowPhosphate: known and potential roles during development and regeneration of teeth and supporting structures.Evaluation of the effects of pulsed wave LLLT on tibial diaphysis in two rat models of experimental osteoporosis, as examined by stereological and real-time PCR gene expression analyses.Removal of pamidronate from bone in rats using systemic and local chelation.Osteoclastogenic activity and RANKL expression are inhibited in osteoblastic cells expressing constitutively active Gα(12) or constitutively active RhoA
P2860
Q24626459-03F12EC0-FA5E-470B-8FE6-354AE02EEF62Q26741243-578BE549-B6EF-499F-AD03-F28C6BBFD1CFQ26752158-31B732B6-E841-4455-9C95-E96AD69896C9Q26775765-A58ECC79-019F-46FC-8CF5-58EF9C72EBACQ26801664-E4B42104-5DAB-46F2-9036-817822EE60F5Q28258154-2BD8AF61-6259-43BC-9B95-5729803EC476Q28569888-675E063B-3841-48DD-A110-D55C7C330566Q29616548-D77E4758-C1E6-4B8E-9C55-0A5B87642628Q30452491-7206D506-46B8-460F-BDF0-39B997092357Q31136234-F6FABE40-32F6-411B-9DA6-04311E6DA6F9Q33432776-120E3289-4A84-4D1A-B405-FC2C7984B23CQ33644647-D1AADF0E-FE21-40E8-895F-E8B4C6FBFBA1Q33771321-0887EB88-746B-4FAE-9DB2-FE980EE6CD50Q33814312-35B1E514-18D8-4FC1-B1E7-725F7474B5C3Q33822541-F61C0B25-A880-413E-8AC1-0FAF8542A9D2Q33864698-3A5D9D4A-0D2A-466D-8BB2-22CA10B9EED8Q33920919-5646160E-F331-4B74-9D86-C6027708A3CEQ33953661-8580ADE2-E895-4709-9740-19AFB2253601Q34133308-961FD17C-550E-463B-A35E-E7C7B2AF3224Q34183161-4234A466-56C4-43C2-BD38-87A43A68034FQ34191657-7EFDD56D-9550-4852-9DD2-4243588824D7Q34365891-5712188E-4B18-4350-9509-5C9639792F6FQ34462037-CDD00316-34DC-4E3A-9EE9-194BAE6B72FAQ34758140-AA217C73-E1BF-4F44-923C-912ED34C587EQ34939979-940AE3C1-0909-42B6-9398-C14B852A04BFQ35458425-9F95ABC7-64B2-4CBF-8F76-DF69533CDF45Q35534524-CC528314-1943-423E-98FE-E455A6748680Q35557938-F7868AA4-6C30-4BAC-86F3-6F12B93E38B0Q35582828-13C13A88-9338-44D4-934C-AD288B01CD76Q35597843-6EA52278-2959-4C70-B6F9-6E9D70E1D3D2Q35723178-8B24DBB1-6CEE-4851-84CC-B623B5122108Q35748623-E538FCC8-2A0F-4666-8F4F-AB5D5AA9D36BQ35762578-A082E42C-935F-4089-8B55-6C632999B851Q35832193-C149DCDA-CE0E-4E8C-A4B8-540B3086A0EBQ35842418-6B79F97F-5101-4A58-9170-2FC67032D2CBQ35853991-CF5D12E9-E0E5-4D37-BE9B-AF891DC380E8Q35920063-6CB48E7B-71C6-4A11-B377-38FF32A4F968Q35953078-97C549B5-8B50-4D0F-8A9A-CBFBE26ECA1AQ36259554-9CDD7620-E1BA-4344-82B7-DC2E94C19C05Q36340904-95A52646-D4E3-4340-9A65-10D86191DF50
P2860
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
2007年论文
@zh
2007年论文
@zh-cn
name
Bisphosphonates: mode of action and pharmacology.
@en
type
label
Bisphosphonates: mode of action and pharmacology.
@en
prefLabel
Bisphosphonates: mode of action and pharmacology.
@en
P356
P1433
P1476
Bisphosphonates: mode of action and pharmacology.
@en
P2093
R Graham G Russell
P304
P356
10.1542/PEDS.2006-2023H
P407
P478
119 Suppl 2
P577
2007-03-01T00:00:00Z